TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04975997
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
Study: NCT04975997
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
Study: NCT04975997
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
Study: NCT04975997
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
Study: NCT06680830
Drug: NEU-411
Normalized name: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPP
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEU-411, a potent, selective, orally bioavailable, highly permeable, brain penetrant, small molecule inhibitor of LRRK2 activity
Study: NCT06692673
Drug: Use of Linaclotide as a single agent Colonoscopy prep
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: We plan to conduct a pilot study to determine the feasibility of a quality bowel preparation with two 290mg doses of Linaclotide (first dose given 36 hours before, and the other 8 hours prior to the procedure) along with 2 Liters of Gatorade (to prevent dehydration) given the day prior to the colonoscopy instead of the current standard 4 liters of PEG regimen. All study participants will be asked to consume a clear liquid diet for 24hours before the procedure.
Study: NCT05275686
Drug: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
Normalized name: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
Study: NCT06006143
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive a prescription for varenicline and will meet with a clinical pharmacist and addiction psychiatrist for further support
Study: NCT05447208
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
Study: NCT06479161
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.95 grams oral
Study: NCT05447208
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Study: NCT05162352
Drug: Donafenib+sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 (Safety Run-in): donafenib 200mg P.O. BID and sintilimab 200mg I.V. for a 21-days cycle.~Part 2: donafenib at the recommended phase 2 dose determined from Part 1 and sintilimab 200mg I.V. Q3W.~Donafenib will last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Sintilimab will last up to 24 months, or until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. Patients will be allowed to have donafenib or sintilimab as a sigle agent and will be still considered on study when the other drug cause intolerable toxicity.
Study: NCT06466798
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab infusions will be given intraventricularly once every other week for 12 weeks. Dosing will be based upon patient body weight.
Study: NCT06466798
Drug: 5-Azacytidine
Normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg 5-Azacytidine infusions will be given intraventricularly once weekly for twelve consecutive weeks.
Study: NCT05904080
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT06682780
Drug: LM-2417
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q2W/Q3W,Intravenous Drip
Study: NCT06682780
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Q3W,Intravenous Drip
Study: NCT06682780
Drug: Toripalimab/Tirelizumab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q3W,Intravenous Drip
Study: NCT06682780
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Q3W,Intravenous Drip
Study: NCT06682780
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: QD,Oral Administration
Study: NCT06682780
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: QD,Oral Administration
Study: NCT06088004
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1 antibody
Study: NCT06192927
Drug: 0.9% Sodium Chloride Injection
Normalized name: SODIUM CHLORIDE 9 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [0.9% Sodium Chloride Injection, 500mL, DRE BioLab, TotalCare]
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single subcutaneous injection
Study: NCT05401110
Drug: Osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib given by mouth daily at 40mg or 80mg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
Study: NCT05401110
Drug: Carotuximab
Normalized name: Carotuximab
DrugBank: Carotuximab (DB06322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carotuximab is administered intravenously weekly for the first 4 weeks, then every 2 weeks at 10mg/kg or 15 mg/kg depending on the starting dose level assigned per investigator. Therapy will continue until disease progression, patient withdrawal, or treatment intolerance.
Study: NCT06302140
Drug: Nanatinostat (free base) tablets in combination with Valganciclovir
Normalized name: valganciclovir Oral Tablet
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment A: a single, oral dose of nanatinostat (free base) tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
Study: NCT06302140
Drug: Nanatinostat mesylate tablets in combination with Valganciclovir
Normalized name: valganciclovir Oral Tablet
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment B: a single, oral dose of nanatinostat mesylate tablets (20 mg) in combination with valganciclovir (900 mg) under fed conditions.
Study: NCT06302140
Drug: Single-agent Nanatinostat (free base) tablets
Normalized name: Panobinostat
DrugBank: Nanatinostat (DB15419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg once daily under fed conditions until disease progression or unacceptable toxicity, whichever occurs first.
Study: NCT05917860
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Degarelix is injected subcutaneously into the fatty tissue of the abdomen. A typical protocol consists of a starting dose of 240 mg with a maintenance dose of 80 mg administered every 28 days. In this study, one starting dose and two maintenance doses of Degarelix will be administered between baseline and TULSA treatment in accordance with the terms of Degarelix marketing authorizations.
Study: NCT05798195
Drug: Dexamethasone oral tablet
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: treat with Dexamethasone for 2 weeks
Study: NCT06137638
Drug: ENA-001
Normalized name: ENA-001
DrugBank: ENA-001 (DB18153)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENA-001 will be prepared in Ringer's lactate solution. A loading dose will be administered for 20 minutes followed by continuous infusion until the patient meets the criteria for PACU discharge (≥ 9 Aldrete score) or ABG reveals PaCO2 \< 30 mmHg with pH in the normal range. ENA-001 is for IV injection ready for use per subject by the investigational pharmacy, according to the randomization schedule.
Study: NCT06619600
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dapagliflozin 10 mg qd
Study: NCT06512051
Drug: SHR-A2102；Adebrelimab；Cisplatin/ Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: SHR-A2102~Drug: Adebrelimab~Drug: Cisplatin/ Carboplatin
Study: NCT05163366
Drug: GROUP A
Normalized name: Blood group A IgM
DrugBank: Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen (DB10798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal Ketamine will be administered at 6 mg/kg and with a rectal nozzle it's infused through the rectum. The rectal ketamine will be administered after scoring pain just before the start of the procedure and then about 15 minutes later the procedure will start when the patient has achieved a nystagmus.
Study: NCT05163366
Drug: GROUP B
Normalized name: Blood group B IgM
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The tradition standard protocols involve the use of 0.3mg/kg of oral morphine about an hour before the start of the procedure before the start of the procedure to allow for the onset of action of oral morphine for every single procedure in this arm.
Study: NCT05377489
Drug: RTX-GRT7039
Normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RTX-GRT7039 monoarticular injections or bilateral intra-articular injections.
Study: NCT04756687
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05761860
Drug: OxyCODONE 5 mg Oral Tablet
Normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 5mg oral administration
Study: NCT05761860
Drug: OxyCODONE 2.5 mg Oral Tablet
Normalized name: ASA 325 MG / Oxycodone 2.5 MG Oral Tablet
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 2.5mg oral administration
Study: NCT05761860
Drug: Oxytocin Nasal Spray (48 IU)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin administration (48 IU)
Study: NCT04819269
Drug: Tivanisiran sodium ophthalmic solution
Normalized name: sodium chloride Ophthalmic Ointment
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop in the affected eye(s) once daily
Study: NCT04819269
Drug: Vehicle ophthalmic solution
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in the affected eye(s) once daily
Study: NCT06029673
Drug: Cabergoline 1 MG
Normalized name: cabergoline 1 MG
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine agonist
Study: NCT05239793
Drug: NJOY e-cigarette
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NJOY e-cigarette with Virginia Tobacco flavored 5% nicotine pods
Study: NCT05847257
Drug: Letrozole tablets
Normalized name: Letrozole Tablets
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: letrozole 2.5mg twice weekly for 3 months
Study: NCT05357989
Drug: buntanetap/posiphen
DrugBank: Posiphen (DB15317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPMC (vegetarian source) capsule shells
Study: NCT03984565
Drug: Cannabidiol
Normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: High-CBD, low-THC sublingual product formulated in palm oil
Study: NCT05564650
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05564650
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05694715
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally
Study: NCT05694715
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV)
Study: NCT05714072
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg BID or 15mg BID
Study: NCT05714072
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50, 100 and 150 mg
Study: NCT06073132
Drug: AC-203
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigational product is formulated as 1% topical ointment
Study: NCT06063967
Drug: Risankizumab SC
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous (SC) injection
Study: NCT06063967
Drug: Placebo for risankizumab
Normalized name: risankizumab
DrugBank: Risankizumab (DB14762)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous (SC) injection
Study: NCT05789043
Drug: camrelizumab+apatinib+TMZ
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab 200mg，q2w+apatinib 250mg，qd+TMZ 200mg/m2，day1-5/28
Study: NCT05789043
Drug: camrelizumab+apatinib
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab 200mg，q2w+apatinib 250mg qd
Study: NCT05789043
Drug: camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab 200mg，q2w
Study: NCT06318273
Drug: ABBV-969
Normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT06043427
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m²
Study: NCT06043427
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg
Study: NCT06043427
Drug: Zanidatamab
Normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose and schedule to be assigned at enrollment
Study: NCT05730036
Drug: Linvoseltamab
Normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN5458 will be administered by intravenous (IV) infusion
Study: NCT05730036
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab will be administered by IV infusion
Study: NCT05730036
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide capsules will be administered by mouth (PO)
Study: NCT05730036
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone tablets/capsules will be administered PO and/or by IV infusion
Study: NCT06356012
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.
Study: NCT05169112
Drug: Lupron Depot
Normalized name: Lupron Depot
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to receive androgen deprivation therapy (ADT) will receive 12 months of Lupron Depot (22.5 mg) administered every 3 months
Study: NCT05940493
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet
Study: NCT06489431
Drug: Chlorhexidine
Normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Irrisept is a self-contained jet lavage that contains chlorhexidine gluconate (CHG) as a preservative to offer broad-spectrum activity against various microorganisms in the bottled solution
Study: NCT06489431
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial known to inhibit DNA-dependent RNA polymerase
Study: NCT05850520
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreally (IVT) injection.
Study: NCT05850520
Drug: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreally (IVT) injection.
Study: NCT05193838
Drug: Allopurinol Tablet
Normalized name: Allopurinol Tablets
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: examined patients with dilated cardiomyopathy will receive allopurinol for 6 months
Study: NCT04994509
Drug: Oral Lenacapavir (LEN)
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally without regard to food
Study: NCT04994509
Drug: Subcutaneous (SC) Lenacapavir (LEN)
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via SC injections
Study: NCT04994509
Drug: F/TAF
Normalized name: Emtricitabine/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets administered orally
Study: NCT04994509
Drug: F/TDF
Normalized name: Emtricitabine/Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT04994509
Drug: PTM Oral LEN
Normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally
Study: NCT05118789
Drug: NVL-520
Normalized name: NVL-655
DrugBank: NVL-655 (DB18682)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet of NVL-520
Study: NCT06315881
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insert low FBN R/S ONP
Study: NCT06315881
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insert low FBN \> 99% S ONP
Study: NCT06315881
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insert high R/S ONP
Study: NCT06315881
Drug: Nicotine Oral Pouch
Normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insert high FBN \> 99% ONP
Study: NCT06315881
Drug: Smokeless Tobacco
Normalized name: Tobacco leaf
DrugBank: Tobacco leaf (DB10710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insert ST
Study: NCT04869137
Drug: Lenvatinib Oral Product
Normalized name: lenvatinib Oral Product
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20mg of Lenvatinib will be taken orally once daily
Study: NCT04869137
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg of Pembrolizumab will be administered through IV infusion every 3 weeks.
Study: NCT05667805
Drug: Prothrombin Complex Concentrate
Normalized name: Prothrombin complex concentrate
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal use (standard treatment)
Study: NCT05021562
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Niraparib capsules
Study: NCT05577910
Drug: Topical eye drops (Hypromellose, 3mg/ml)
Normalized name: Soothe Lubricant Eye Drops
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will be given one single topical lubricant (Hypromellose, 3mg/ml) to be used as frequently as needed from recruitment to study exit (total 16 months).
Study: NCT06087263
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given by PO
Study: NCT06343376
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT05145361
Drug: B001 injection
DrugBank: KB001 (DB05222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B001 injection 50mg/5mL Intravenous solution
Study: NCT06780215
Drug: Varenicline Tartrate Tablets
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in treatment group take varenicline tartrate tablets according to the following regimen:~Days 1-3: 0.5 mg/dose, once daily. Days 4-42: 0.5 mg/dose, twice daily, taken orally at the same time each morning and evening (the dosing interval is recommended to be 12 h ± 2 h).~Days 43-45: 0.5 mg/dose, once daily.